Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France.

IF 2.8 2区 医学 Q2 UROLOGY & NEPHROLOGY
Sylvie Negrier, Julia Bonastre, Florian Colrat, Siguroli Teitsson, Christopher Knight, Lei Ni, Julie Chevalier, Sébastien Branchoux, Morgan Rouprêt
{"title":"Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France.","authors":"Sylvie Negrier, Julia Bonastre, Florian Colrat, Siguroli Teitsson, Christopher Knight, Lei Ni, Julie Chevalier, Sébastien Branchoux, Morgan Rouprêt","doi":"10.1007/s00345-025-05589-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the cost-effectiveness of nivolumab for adjuvant treatment of adults with muscle-invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) and tumour cell expression PD-L1 ≥ 1% following radical resection from the payer perspective in France.</p><p><strong>Methods: </strong>A four-state (disease-free, loco-regional recurrence, distant recurrence, death) semi-Markov model was developed to simulate health outcomes and costs in a cohort of patients with MIUC-HR and tumour cell expression PD-L1 ≥ 1% following radical resection. Health state-specific costs and quality of life-adjusted life years (QALYs) were compared between two treatment strategies (nivolumab, surveillance). The time horizon was 15 years. Clinical and utility inputs were modelled from the data obtained in the Phase III trial CheckMate 274 (#NCT02632409). Cost inputs were extracted from French sources (notably the French National Cost Study). Model outputs were life-years and QALYs overall and by health-state, total costs and cost components. The incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) between the two treatment strategies were calculated.</p><p><strong>Results: </strong>Life-years were 7.3 for nivolumab and 5.2 for surveillance; QALYs were 4.7 for nivolumab and 3.3 for surveillance. The between-strategy difference in QALYs was essentially accrued in the disease-free state (nivolumab: 4.2, surveillance: 2.6). Total costs were €129,150 for nivolumab and €93,031 for surveillance. The principal cost components were nivolumab acquisition (€ 44,054) and disease management (nivolumab: €29,831; surveillance: €27,233). The estimated ICER was € 17,228/LY gained and the estimated ICUR was €25,806/QALY.</p><p><strong>Conclusion: </strong>Nivolumab in the adjuvant setting is likely to be cost-effective compared to surveillance in France.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":"43 1","pages":"202"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961515/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00345-025-05589-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate the cost-effectiveness of nivolumab for adjuvant treatment of adults with muscle-invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) and tumour cell expression PD-L1 ≥ 1% following radical resection from the payer perspective in France.

Methods: A four-state (disease-free, loco-regional recurrence, distant recurrence, death) semi-Markov model was developed to simulate health outcomes and costs in a cohort of patients with MIUC-HR and tumour cell expression PD-L1 ≥ 1% following radical resection. Health state-specific costs and quality of life-adjusted life years (QALYs) were compared between two treatment strategies (nivolumab, surveillance). The time horizon was 15 years. Clinical and utility inputs were modelled from the data obtained in the Phase III trial CheckMate 274 (#NCT02632409). Cost inputs were extracted from French sources (notably the French National Cost Study). Model outputs were life-years and QALYs overall and by health-state, total costs and cost components. The incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) between the two treatment strategies were calculated.

Results: Life-years were 7.3 for nivolumab and 5.2 for surveillance; QALYs were 4.7 for nivolumab and 3.3 for surveillance. The between-strategy difference in QALYs was essentially accrued in the disease-free state (nivolumab: 4.2, surveillance: 2.6). Total costs were €129,150 for nivolumab and €93,031 for surveillance. The principal cost components were nivolumab acquisition (€ 44,054) and disease management (nivolumab: €29,831; surveillance: €27,233). The estimated ICER was € 17,228/LY gained and the estimated ICUR was €25,806/QALY.

Conclusion: Nivolumab in the adjuvant setting is likely to be cost-effective compared to surveillance in France.

在法国,纳武单抗与辅助治疗肌肉侵袭性尿路上皮癌复发率高的监测的成本-效果比较
目的:从付款人的角度评估nivolumab辅助治疗法国根治后复发风险高(MIUC-HR)且肿瘤细胞表达PD-L1≥1%的成人肌肉侵袭性尿路上皮癌的成本-效果。方法:建立四状态(无病、局部复发、远处复发、死亡)半马尔可夫模型,模拟MIUC-HR和肿瘤细胞表达PD-L1≥1%的患者根治性切除后的健康结果和成本。比较两种治疗策略(纳沃单抗和监测)的健康状况特异性成本和生活调整生命年质量(QALYs)。时间范围是15年。临床和效用输入根据III期试验CheckMate 274 (#NCT02632409)获得的数据进行建模。费用投入来自法国来源(特别是法国国家成本研究)。模型输出是总体生命年和质量年,并按健康状况、总成本和成本组成部分分列。计算两种治疗策略的增量成本-效果比(ICER)和增量成本-效用比(ICUR)。结果:纳武单抗组为7.3年,监测组为5.2年;纳武单抗的QALYs为4.7,监测的QALYs为3.3。QALYs的策略间差异基本上是在无病状态下累积的(nivolumab: 4.2,监测:2.6)。纳武单抗的总成本为129,150欧元,监测成本为93,031欧元。主要成本组成部分是纳武单抗采购(44,054欧元)和疾病管理(纳武单抗:29,831欧元;监测:€27233)。ICUR估计为17228欧元/年,ICUR估计为25806欧元/年。结论:在法国,与监测相比,Nivolumab在辅助治疗中可能具有成本效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World Journal of Urology
World Journal of Urology 医学-泌尿学与肾脏学
CiteScore
6.80
自引率
8.80%
发文量
317
审稿时长
4-8 weeks
期刊介绍: The WORLD JOURNAL OF UROLOGY conveys regularly the essential results of urological research and their practical and clinical relevance to a broad audience of urologists in research and clinical practice. In order to guarantee a balanced program, articles are published to reflect the developments in all fields of urology on an internationally advanced level. Each issue treats a main topic in review articles of invited international experts. Free papers are unrelated articles to the main topic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信